Transcriptomic FHIT/pHER2 signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer.

Fiche publication

Date publication

décembre 2022

Journal

Frontiers in immunology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DALSTEIN Véronique , Pr POLETTE Myriam , Dr NAWROCKI-RABY Béatrice , Pr GERMAIN Adeline , Dr DORMOY Valerian

Tous les auteurs :
Brisebarre A, Ancel J, Ponchel T, Loeffler E, Germain A, Dalstein V, Dormoy V, Durlach A, Delepine G, Deslée G, Polette M, Nawrocki-Raby B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36544755

Résumé

In recent decades, the development of immunotherapy and targeted therapies has considerably improved the outcome of non-small cell lung cancer (NSCLC) patients. Despite these impressive clinical benefits, new biomarkers are needed for an accurate stratification of NSCLC patients and a more personalized management. We recently showed that the tumor suppressor fragile histidine triad (FHIT), frequently lost in NSCLC, controls HER2 receptor activity in lung tumor cells and that tumor cells from NSCLC patients harboring a FHIT/pHER2 phenotype are sensitive to anti-HER2 drugs. Here, we sought to identify the transcriptomic signature of this phenotype and evaluate its clinical significance.